Welcome to the Media Centre
This section provides details of new items added to the site as well as a full archive of our press releases and statements.
The opening hours for the Press Office are Monday to Friday between 9:00 and 17:00.
The Press Office
151 Buckingham Palace Road
Main telephone: 020 3080 7651
Out of hours: 07770 446 189
For urgent calls outside these press office hours please contact the duty press officer on : 07770 446 189.
We now have a Twitter channel for press releases and news statements, giving you another way to find out the latest news from the MHRA in real time.Follow @MHRApress
Press enquiries should be made through the Press Office.
Latest news and press releases
21 Oct 2014 | MHRA responds to article in The Sun on breast implants
MHRA responds to was an article in The Sun regarding rise in reports on adverse incidents in relation to breast implants.
17 Oct 2014 | Press release: Regulator warns dentists about the dangers of buying and using counterfeit and unapproved dental equipment
The Medicines and Healthcare products Regulatory Agency (MHRA) is warning dentists about the potential danger of buying and using counterfeit and unapproved dental equipment. This follows the seizure of over 12,000 different pieces of poor quality dental equipment imported into the UK from China and Pakistan and sold on auction websites such as eBay, Amazon and Alibaba in the past 6 months.
17 Oct 2014 | MHRA statement on misuse of laxatives
MHRA has issued a statement following the BBC Watchdog investigation into the availability of stimulant laxatives in the UK, first broadcast on Thursday 16 October.
13 Oct 2014 | Press release: ‘One stop shop’ for advice on regenerative medicine opening for business
A new ‘one stop shop’ that will provide regulatory advice for those working in the life sciences industry on exciting regenerative medicines has been launched today.
10 Oct 2014 | Press release: MHRA responds to European Medicines Agency recommendations on the use of valproate medicines
The Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) has recommended strengthening the restrictions on the use of valproate medicines due to an increased risk of birth defects and developmental problems in children exposed to valproate in the womb.
Photo and image library
This section of the site includes press releases and statements issued by the MHRA.